New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareProstamax vs IGF-1 LR3

Prostamax vs IGF-1 LR3

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Prostamax
Anabolic & IGF
IGF-1 LR3
Summary
Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
IGF-1 LR3 is a synthetic analog of Insulin-like Growth Factor-1 with an extended half-life. It is one of the most potent anabolic peptides available, directly stimulating muscle cell hyperplasia and hypertrophy, and is the downstream mediator of many of GH's anabolic effects.
Half-Life
Short (minutes); sustained gene-regulatory effects
20–30 hours
Admin Route
SubQ, Oral
SubQ, IM
Research
Typical Dose
10 mg per day
40–80 mcg
Frequency
Daily for 10–30 days
Once daily or split twice daily
Key Benefits
  • Supports normalization of prostate tissue architecture
  • May reduce prostate enlargement associated with BPH
  • Anti-inflammatory effects on prostatic tissue
  • Reduces prostate cell apoptosis from oxidative stress
  • Potential support in chronic prostatitis
  • Anti-aging effects on prostate glandular tissue
  • Complementary to conventional BPH therapies
  • Direct muscle hypertrophy via IGF-1R stimulation
  • Muscle hyperplasia (new fiber formation) — unique among peptides
  • Rapid gains in lean muscle mass
  • Accelerated recovery from training and injury
  • Increased nutrient uptake by muscle cells
  • Fat oxidation enhancement
  • Bone density improvement
  • Cartilage and connective tissue repair
Side Effects
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse urological events reported at standard doses
  • Hypoglycemia (significant risk — insulin-like activity)
  • Acromegaly-like effects with excessive long-term use
  • Jaw and hand swelling
  • Organ hypertrophy with extreme doses
  • +2 more
Stacks With